Vasoactive and inflammatory mediators cause capillary leakage, which may form the basis for macular edema
and breakdown of the aqueous blood barrier, resulting in anterior uveitis and periphlebitis.
ILUVIEN is a unique product that addresses a clear unmet need for patients suffering from diabetic macular edema
, and we are very excited about the prospect of making it available to Canadian patients.
The FDA previously had approved Lucentis to treat DME and macular edema
secondary to retinal vein occlusions, both of which cause fluid to leak into the macula resulting in blurred vision.
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema
due to retinal vein occlusion.
Devise corrective measures for pipeline projects by understanding Macular Edema
pipeline depth and focus of Indication therapeutics.
VIBRANT was a Phase 3, randomized, double-masked, active-controlled 52-week study, comparing aflibercept solution for injection 2 milligram (mg) monthly with laser photocoagulation in subjects with macular edema
secondary to BRVO.
About Diabetic Retinopathy with Diabetic Macular Edema
(DME) Diabetic retinopathy is a common complication of diabetes, causing damage to the retina, which may lead to poor vision and vision loss.
The Company's lead program, AKB9778, is a firstinclass stabilizer of the Tie2 pathway and is in clinical development for diabetic macular edema
7 mg intravitreal implant (Ozurdex, Allergan) under the marketing authorization extension is indicated for adult patients with visual impairment due to diabetic macular edema
who are pseudophakic, or who were unable to undertake noncorticosteroid therapy.
The proceeds will support ongoing development of Aerpio's pipeline, including AKB-9778, which is entering Phase 1b/2a for the treatment of diabetic macular edema
EU approval is based on positive data from the Phase 3 VIBRANT study in patients with visual impairment due to macular edema
secondary to BRVO.
Bayer HealthCare announced today that EYLEAA (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of visual impairment due to diabetic macular edema